FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Erasca, Inc. ERAS

Promising (early)   broader-coverage candidate · Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignanci

On FrontierLab's discovery record since 2026-06-18 (9 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-29), not the curated Frontier signal.
Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)
Gross margin
Gross profits / assets0
Rule of 40
Net margin
Cash runway (months)32
PEG
Price / sales

Quality checklist

Fundamentals — snapshot as of 2026-07-29

StageEarly
Share issuance (YoY)7.4% · heavy issuance
Moat
TAM
P/E (trailing)
EPS (trailing)$-0.93
Burn multiple
Gross-margin trend (pts)
Cash / assets0.53
Net debt / EBITDA
Statements as ofQ1 FY2026 · filed 2026-05-11

Momentum context — a snapshot from 2026-07-29, not current

Price at surface$18.16 (as of 2026-07-29)
52-week range$1.33 – $24.28
% off 52-wk high-25.2%
RSI (14)52
Relative volume0.8×

Risk flags

Heavy share dilution (>5%/yr) — your slice shrinks.Parabolic one-day spike (+14%) in the last month — extreme single-day moves tend to mean-revert.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-07-29 (end-of-day). How grades are computed →